Abstracts Archive - Page 18 of 1683 - ATC Abstracts

2022 American Transplant Congress
Novel Biopsy-Based Clinical Phenotype Clustering to Predict Kidney Transplant Outcomes
A. Ahmed¹, L. Allegretti², C. Rebello³, B. Kinsella³, K. Guo³, S. Park⁴, J. Friedewald³
¹Chicago Medical School at Rosalind Franklin University, Chicago, IL, ²University of Wisconsin, Madison, WI, ³Northwestern University, Chicago, IL, ⁴Transplant Nephrology, Northwestern University, Chicago, IL
*Purpose: The purpose of this study was to define novel clinical phenotypes based on biopsy results to enhance biomarker discovery.*Methods: Retrospective analysis of kidney biopsy…
2022 American Transplant Congress
Impact of Cold Ischemia Times on 1 Year Kidney Transplant Outcomes
T. Fletchinger, L. Burdine
Department of Surgery, University of Arkansas for Medical Sciences, Little Rock, AR
*Purpose: Recent organ allocation changes have increased travel and subsequent cold ischemia times (CIT) of kidney allografts. We sought to investigate the impact of prolonged…
2022 American Transplant Congress
A Randomized Phase 2 Study Of Mau868 Vs Placebo To Treat Bk Viremia In Kidney Transplant Recipients
S. Jordan¹, A. P. Limaye², B. Fischbach³, P. Sood⁴, S. Collette⁵, L. Gasink⁶, M. W. Fordyce⁷, C. J. Lin⁷, M. Hodges⁶, D. C. Brennan⁸
¹Cedars-Sinai Medical Center, Los Angeles, CA, ²University of Washington, Seattle, WA, ³Dallas Nephrology Associates, Inc, Dallas, TX, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada, ⁶previous employee/consultant for Amplyx Pharmaceuticals, San Diego, CA, ⁷Vera Therapeutics, Inc, Brisbane, CA, ⁸Johns Hopkins School of Medicine, Baltimore, MD
*Purpose: To assess the safety and efficacy of MAU868, a BK virus-specific monoclonal antibody, in adult kidney transplant recipients with BK viremia.*Methods: This is a…
2022 American Transplant Congress
Evaluation of Donor Exclusion Criteria in Living Donor Liver Transplantation: A Single-Center Experience
D. Daskalaki, M. E. Akoad, J. Kim, C. J. Simon, Y. Cheah
Hepatobiliary Surgery and Liver Transplantation, Lahey Hospital and Medical Center, Burlington, MA
*Purpose: Liver donation is fundamental in increasing the pool of available grafts. Careful evaluation of each donor ensures the best outcomes for the recipient and…
2022 American Transplant Congress
Recipient Treatment with Anti-CD122 mAb Prolongs Kidney Allograft Survival During Antibody-Mediated Rejection without Impacting NK Cell Activation within the Graft
D. Okada, S. Miyairi, N. Dvorina, K. S. Keslar, A. Valujskikh, W. Baldwin, R. Fairchild
Cleveland Clinic, Cleveland, OH
*Purpose: Dysregulated donor-specific antibody (DSA) responses are induced in B6.CCR5-/- mice transplanted with complete MHC mismatched kidney allografts and are required for rejection of the…
2022 American Transplant Congress
Impact of Belatacept Conversion on Renal Function and Donor Specific Antibodies in Renal Transplant Recipients
E. R. Brown, K. Cunningham, K. Paplaczyk, C. Dagostino, C. Kane, A. Shetty
Northwestern Memorial Hospital, Chicago, IL
*Purpose: Although associated with nephrotoxicity, calcineurin inhibitors (CNI) have historically been the cornerstone of immunosuppression. Belatacept, a co-stimulation blocker, is FDA-approved for de novo use…
2022 American Transplant Congress
Baseline Findings from the UREAACT Trial to Improve Medication Adherence in Youth with Kidney Transplants
S. Amaral¹, P. Kwong², J. Zhu², R. George³, N. Rodig⁴, B. Warady⁵, J. Smith⁶, A. Bobrowski⁷, D. Matossian⁸, N. Zelikovsky⁹, L. Schwartz¹, P. Reese², R. Goldfarb Terry¹, J. Reason², A. Chung¹, S. Furth¹
¹CHOP, Phila, PA, ²UPenn, Phila, PA, ³CHOA, Atlanta, GA, ⁴Boston Children's, Boston, MA, ⁵Children's Mercy, Kansas City, MO, ⁶Seattle Children's, Seattle, WA, ⁷Cleveland Clinic, Cleveland, OH, ⁸Lurie Children's, Chicago, IL, ⁹LaSalle Univ, Phila, PA
*Purpose: This abstract describes the design and baseline characteristics of participants in the U-REAACT trial, a study to improve medication adherence in youth with kidney…
2022 American Transplant Congress
Team Decision-Making in Liver Transplant Evaluation: A Multi-Center Ethnographic Observation Study
C. N. Sidoti, H. C. Sung, D. L. Segev, M. L. Levan, T. S. Purnell, A. T. Strauss
Johns Hopkins School of Medicine, Baltimore, MD
*Purpose: Transplant providers are tasked with making ethically complex and high-stakes decisions of determining a patient’s candidacy for liver transplantation within a multi-disciplinary team. We…
2022 American Transplant Congress
Variation in Donor Liver Rejection Rates for Donor Quality Among US Transplant Centers
M. Anderson¹, T. Gilbert², M. Englesbe¹, S. Waits¹
¹Michigan Medicine Transplant Center, Ann Arbor, MI, ²University of Michigan Medical School, Ann Arbor, MI
*Purpose: Optimal utilization of all viable donor livers is a public health imperative. As no standardized criteria exist for assessment of donor quality, differential utilization…
2022 American Transplant Congress
Renal Transplantation and Statins Effects on Dyslipidemia in Renal Transplant Recipients
Z. Arabi, A. Alghamdi, A. Alnasrullah, A. R. Altheaby, M. Tawhari, N. Alnazari
KAMC, Riyadh, Saudi Arabia
*Purpose: to review the effect of renal transplantation and adding of statins on dyslipidemia in renal transplant recipients.*Methods: A single center experience retrospective study of…